WO2008060581A3 - Compositions including triciribine and trastuzumab and methods of use thereof - Google Patents

Compositions including triciribine and trastuzumab and methods of use thereof Download PDF

Info

Publication number
WO2008060581A3
WO2008060581A3 PCT/US2007/023963 US2007023963W WO2008060581A3 WO 2008060581 A3 WO2008060581 A3 WO 2008060581A3 US 2007023963 W US2007023963 W US 2007023963W WO 2008060581 A3 WO2008060581 A3 WO 2008060581A3
Authority
WO
WIPO (PCT)
Prior art keywords
trastuzumab
methods
compositions including
including triciribine
triciribine
Prior art date
Application number
PCT/US2007/023963
Other languages
French (fr)
Other versions
WO2008060581A2 (en
Inventor
Jin Q Cheng
Said M Sebti
Original Assignee
Univ South Florida
Jin Q Cheng
Said M Sebti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ South Florida, Jin Q Cheng, Said M Sebti filed Critical Univ South Florida
Publication of WO2008060581A2 publication Critical patent/WO2008060581A2/en
Publication of WO2008060581A3 publication Critical patent/WO2008060581A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This application relates to combination therapies including triciribine and related compounds and trastuzumab or a salt thereof and compositions with reduced toxicity for the treatment and prevention of tumors, cancer, and other disorders associated with abnormal cell proliferation.
PCT/US2007/023963 2006-11-15 2007-11-15 Compositions including triciribine and trastuzumab and methods of use thereof WO2008060581A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85892306P 2006-11-15 2006-11-15
US60/858,923 2006-11-15

Publications (2)

Publication Number Publication Date
WO2008060581A2 WO2008060581A2 (en) 2008-05-22
WO2008060581A3 true WO2008060581A3 (en) 2008-08-21

Family

ID=39402253

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/023963 WO2008060581A2 (en) 2006-11-15 2007-11-15 Compositions including triciribine and trastuzumab and methods of use thereof

Country Status (2)

Country Link
TW (1) TW200827363A (en)
WO (1) WO2008060581A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110223154A1 (en) 2008-05-12 2011-09-15 University Of South Florida Compositions including triciribine and methods of use thereof
WO2008057503A2 (en) * 2006-11-06 2008-05-15 Vioquest Pharmaceuticals, Inc. Compositions including triciribine and taxanes and methods of use thereof
WO2009139766A1 (en) * 2008-05-12 2009-11-19 University Of South Florida Anticancer combination therapy including triciribine

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005094322A2 (en) * 2004-03-29 2005-10-13 University Of South Florida Effective treatment of tumors and cancer with triciribine and related compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005094322A2 (en) * 2004-03-29 2005-10-13 University Of South Florida Effective treatment of tumors and cancer with triciribine and related compounds

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ERIKO TOKUNAGA ET AL: "Trastuzumab and breast cancer: developments and current status", INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, SPRINGER-VERLAG, TO, vol. 11, no. 3, 1 June 2006 (2006-06-01), pages 199 - 208, XP019387233, ISSN: 1437-7772 *
LU CHIEN-HSING ET AL: "Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, vol. 13, no. 19, 1 October 2007 (2007-10-01), pages 5883 - 5888, XP002472826, ISSN: 1078-0432 *

Also Published As

Publication number Publication date
WO2008060581A2 (en) 2008-05-22
TW200827363A (en) 2008-07-01

Similar Documents

Publication Publication Date Title
PH12015500248A1 (en) Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
WO2007139955A8 (en) Triazole compounds that modulate hsp90 activity
WO2007139967A3 (en) Triazole compounds that modulate hsp90 activity
WO2007139968A3 (en) Triazole compounds that modulate hsp90 activity
WO2007146957A3 (en) Ror1 as a therapeutic target for lung cancer
MX2010001565A (en) Triazole compounds that modulate hsp90 activity.
MX2009008547A (en) Triazole compounds that modulate hsp90 activity.
WO2007053573A3 (en) Treatment of cancer with sorafenib
WO2006091395A3 (en) Inhibitors of akt activity
WO2009045443A3 (en) Methods and compositions related to synergistic responses to oncogenic mutations
WO2010058032A3 (en) Substituted pyrimidines for the treatment of diseases such as cancer
WO2008070041A3 (en) Inhibitors of akt activity
WO2008127594A3 (en) Combination therapies comprising quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer
WO2006135627A3 (en) Inhibitors of akt activity
TW200738234A (en) Triazole compounds that modulate HSP90 activity
WO2007139960A3 (en) Compounds that modulate hsp90 activity and methods for identifying same
WO2008031551A3 (en) Non-neuroendocrine cancer therapy
WO2009129246A3 (en) Compositions and methods for preparing and using same
WO2008089397A3 (en) Adrb2 cancer markers
WO2008030883A3 (en) Treatment of cancer
AU2008339918A1 (en) Medicament for the treatment of cancer of the pancreas
WO2006110638A3 (en) Inhibitors of akt activity
WO2008112290A3 (en) Use of ephb4 as a diagnostic marker and a therapeutic target for ovarian cancer
WO2007146335A3 (en) Compounds and compositions for treatment of cancer
WO2007144057A3 (en) Antimicrobial carbon

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07867454

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 07867454

Country of ref document: EP

Kind code of ref document: A2